Introduction Hypertension in pregnancy is still a major risk factor for maternal and fetal morbidity all over the world. Changes in coagulation tests are seen in patients with pre-eclampsia and is important to understand its significance in planning management of patients with pre-eclampsia.
Objective The objective of this study was to evaluate the clinical utility of coagulation screen in clinical management of patients with preeclampsia.
Materials and Methods This was a retrospective cohort study of women with hypertension in pregnancy during the period from January 2008 to July 2009 in West Cumberland Hospital. These women were evaluated for severity of pre-eclampsia and also for any coagulation abnormalities (prothrombin time, partial thromboplastin time and fibrinogen).
Results 104 women were included in the study. Thrombocytopenia (platelets <150 000) is one of the indicators of severity of disease. Using thrombocytopenia as a indicator of severity of the disease, coagulation screen had a sensitivity of only 4%. Also coagulation screen is more expensive and time consuming compared to determination of platelet count. Thus coagulation screen should not be considered as a first line investigation of women with normal platelets in pre-eclampsia.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.